These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 2784473

  • 1. [Low susceptibility of choriocarcinoma cell lines to lymphokine activated killer (LAK) cells].
    Kameda T, Negoro T, Hagiwara M, Koyama M, Matsuzaki N, Saji F, Tanizawa O.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):1-6. PubMed ID: 2784473
    [Abstract] [Full Text] [Related]

  • 2. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ, Krosnick JA, Rosenberg SA.
    J Immunol; 1989 Jan 15; 142(2):726-33. PubMed ID: 2783444
    [Abstract] [Full Text] [Related]

  • 3. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA, Vujanovic NL, Herberman RB, Hiserodt JC.
    J Immunol; 1988 Apr 15; 140(8):2846-52. PubMed ID: 3258622
    [Abstract] [Full Text] [Related]

  • 4. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M, Hasegawa H, Nakayabu M, Fukai K, Suzuki S.
    J Clin Lab Immunol; 1993 Apr 15; 40(2):47-60. PubMed ID: 7932628
    [Abstract] [Full Text] [Related]

  • 5. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
    Ferrini S, Miescher S, Zocchi MR, von Fliedner V, Moretta A.
    J Immunol; 1987 Feb 15; 138(4):1297-302. PubMed ID: 3100633
    [Abstract] [Full Text] [Related]

  • 6. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
    Kaufmann Y, Levanon M, Davidsohn J, Ramot B.
    J Immunol; 1987 Aug 01; 139(3):977-82. PubMed ID: 3496395
    [Abstract] [Full Text] [Related]

  • 7. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
    Hermann GG, Zeuthen J, Claësson MH.
    Nat Immun; 1992 Aug 01; 11(1):7-16. PubMed ID: 1611282
    [Abstract] [Full Text] [Related]

  • 8. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y, Zighelboim J, Berek JS, Bonavida B.
    Nat Immun Cell Growth Regul; 1990 Aug 01; 9(4):283-96. PubMed ID: 2215516
    [Abstract] [Full Text] [Related]

  • 9. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW, Shamim F, Hamon M, Macdonald ID, Prentice HG.
    Exp Hematol; 1995 Dec 01; 23(14):1530-4. PubMed ID: 8542943
    [Abstract] [Full Text] [Related]

  • 10. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG, Abraham SR, Owen-Schaub LB, Hemingway LL, Hemstreet GP, DeBault LE.
    Cancer Res; 1988 Apr 15; 48(8):2184-92. PubMed ID: 3258186
    [Abstract] [Full Text] [Related]

  • 11. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T, Belfrage H, Bhiladvala P, Hedlund G.
    J Immunol; 1987 Jun 01; 138(11):3640-5. PubMed ID: 3495566
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.
    Fierro MT, Liao XS, Lusso P, Bonferroni M, Matera L, Cesano A, Lista P, Arione R, Forni G, Foa R.
    Leukemia; 1988 Jan 01; 2(1):50-4. PubMed ID: 3257539
    [Abstract] [Full Text] [Related]

  • 15. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
    Lanza LA, Wilson DJ, Ikejiri B, Roth JA, Grimm EA.
    J Immunol; 1986 Oct 15; 137(8):2716-20. PubMed ID: 3489774
    [Abstract] [Full Text] [Related]

  • 16. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD, Economou JS, Shau H, Golub SH.
    J Surg Res; 1993 Nov 15; 55(5):486-92. PubMed ID: 8231167
    [Abstract] [Full Text] [Related]

  • 17. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL, Herberman RB, Hiserodt JC.
    Cancer Res; 1988 Feb 15; 48(4):878-83. PubMed ID: 3257411
    [Abstract] [Full Text] [Related]

  • 18. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB, Itoh K, Balch CM.
    J Immunol; 1987 Feb 15; 138(4):1068-73. PubMed ID: 3100627
    [Abstract] [Full Text] [Related]

  • 19. Characterization of effector-target conjugates for cloned human natural killer and human lymphokine activated killer cells by flow cytometry.
    Callewaert DM, Radcliff G, Waite R, LeFevre J, Poulik MD.
    Cytometry; 1991 Feb 15; 12(7):666-76. PubMed ID: 1782834
    [Abstract] [Full Text] [Related]

  • 20. Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma.
    Tong AW, Lee JC, Wang RM, Ordonez G, Stone MJ.
    Cancer Res; 1989 Aug 01; 49(15):4103-8. PubMed ID: 2545333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.